PCI高危患者早期停用阿司匹林对比双联抗血小板治疗的随机试验荟萃分析
该荟萃分析纳入7项随机试验共27743例PCI后高危患者,比较早期停用阿司匹林(≤3个月)转为替格瑞洛或普拉格雷单药治疗与继续DAPT。结果显示P2Y12抑制剂单药降低出血风险(HR=0.55),整体不显著增加心梗(HR=1.11),但立即停用阿司匹林增加心梗(HR=1.41),早期停用则无此风险。
要点
- PCI后高危患者早期停用阿司匹林转P2Y12单药可显著降低出血,不增加心梗。
- 立即停用或未启动阿司匹林增加心梗风险,应避免。
- 停用时机应个体化,高出血风险可≤1个月,高缺血风险可3个月。
核心结论
- 在替格瑞洛或普拉格雷治疗的高危PCI后患者中,3个月内停用阿司匹林较DAPT减少出血且无缺血代价。
- 立即停用或未启动阿司匹林应避免,停药时机应根据出血和缺血风险个体化。
研究设计与样本
- 随机试验的荟萃分析,检索自建库至2025年8月。
- 共纳入7项试验,n=27,743,比较早期停用阿司匹林(≤3个月)转为替格瑞洛或普拉格雷单药与继续DAPT。
主要发现
- P2Y12抑制剂单药降低出血(HR=0.55,95%CI [0.42,0.71],p<0.001)。
- 整体不显著增加心梗(HR=1.11,95%CI [0.91,1.35],p=0.31),未增加死亡、卒中或支架血栓。
- 立即停用/未启动阿司匹林增加心梗(HR=1.41,95%CI [1.01,1.97],p=0.04),早期停用无增加(HR=0.97,95%CI [0.76,1.24],p=0.82)。
- 高出血风险者≤1个月停用阿司匹林出血获益后验概率100%(NNT=12),心梗安全概率70%。
- 高缺血风险者3个月停用阿司匹林出血获益后验概率100%(NNT=57),心梗安全概率86%。
关键数值与推荐
- 早期停用阿司匹林定义为≤3个月,分为立即(未启动或院内停用)和早期(出院后3个月内停用)。
- 主要终点为心梗和临床相关出血。
临床怎么用
- 高出血风险PCI后患者可考虑≤1个月停用阿司匹林转为P2Y12单药。
- 高缺血风险患者可考虑3个月时停用阿司匹林。
- 避免立即停用或未启动阿司匹林。
局限性
- 仅基于聚合数据。
- 立即停用阿司匹林亚组精度有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients at high ischemic or bleeding risk after percutaneous coronary intervention (PCI) require protection against thrombotic events with dual antiplatelet therapy (DAPT) while avoiding bleeding. Although guidelines recommend 12-month DAPT after acute coronary syndrome (ACS), recent trials have tested the safety of early aspirin withdrawal with potent P2Y12-inhibitor monotherapy. METHODS AND FINDINGS: We performed a meta-analysis of randomized trials (from inception through August 2025) comparing early aspirin withdrawal (≤3 months) with transition to ticagrelor- or prasugrel-monotherapy versus continued DAPT. Co-primary outcomes were myocardial infarction (MI) and clinically relevant bleeding. Prespecified timing analyses stratified the comparison versus DAPT by aspirin timing: immediate (aspirin noninitiation or in-hospital cessation) and early (post-discharge discontinuation within 3 months). Bayesian models quantified risk-stratified probabilities of benefit and harm; trial sequential analysis (TSA) assessed conclusiveness of evidence. Seven trials (n = 27,743) were included. P2Y12-inhibitor monotherapy reduced bleeding (HR = 0.55, 95% CI [0.42, 0.71]; p < 0.001) without significantly increasing MI overall (HR = 1.11, 95% CI [0.91, 1.35]; p = 0.31), death, stroke, or stent thrombosis. Immediate aspirin noninitiation/cessation increased MI (HR = 1.41, 95% CI [1.01, 1.97]; p = 0.04), whereas early discontinuation did not (HR = 0.97, 95% CI [0.76, 1.24]; p = 0.82). TSA indicated conclusiveness for bleeding benefit and futility for an MI excess. Analyses restricted to ACS confirmed the overall results. Bayesian analyses corroborated these effects and identified risk-aligned timing: in high bleeding risk, ≤1-month aspirin discontinuation yielded a 100% posterior probability of bleeding benefit (NNT = 12) and 70% probability of MI-safety; in high ischemic risk, 3-month aspirin discontinuation yielded 100% probability of bleeding benefit (NNT = 57) and 86% probability of MI-safety. Limitations include aggregate data only and limited precision for the immediate aspirin withdrawal subgroup. CONCLUSIONS: Among high-risk post-PCI patients on ticagrelor/prasugrel, discontinuing aspirin within 3 months reduces bleeding without an ischemic trade-off versus DAPT. Immediate aspirin noninitiation or cessation should be avoided; timing should be individualized to bleeding and ischemic risk. PROSPERO: CRD420251167706.
引用
- Navarese EP, Gurbel P, Tantry U, et al. Early aspirin withdrawal versus dual antiplatelet therapy in high-risk patients after percutaneous coronary intervention: Meta-analysis of randomized trials. PLoS Med. 2026. PMID: 41886437. doi:10.1371/journal.pmed.1004995
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。